Market growth influenced due to following factors-

• Initiatives undertaken by government and global health organizations.
• Increasing preference for non-invasive procedures, technological advancement to augment market revenues.
• Rising emphasis on personalized medicine, and availability of funding for liquid biopsy R&D.

Global market size-

According to the new market research Liquid Biopsy Market is expected to reach $2,047.9 Million by 2022, at a CAGR of 23.4%. 

Leading Players-

The key players in the global liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).

Top Market Segments-

By product, the assay kits segment is expected to account for the largest share of the market. On the basis of product, the market is broadly segmented into instruments, assays kits, and services. In 2017, the assay kits segment is expected to account for the largest share of this market.

Based on clinical application, the liquid biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The therapy selection segment is expected to account for the largest share of the liquid biopsy devices market in 2017. This is due to the ability of therapy selection to detect advanced-stage cancers (stage III and IV), followed by increasing studies on liquid biopsy and advancements made in this field to also aid in detection of early-stage cancers.

For Details, Download PDF Brochure

Geographic Overview -

North America is expected to account for the largest share of the global liquid biopsy market in 2017, while Asia Pacific is expected to witness the highest growth during 2017 to 2022.